Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)

Sinil Pharmaceutical Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 26, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	68,485	69,054	73,149	87,711	96,840	128,314
Market Cap Growth	-6.52%	-5.60%	-16.60%	-9.43%	-24.53%	-48.11%
Enterprise Value	29,555	31,172	41,173	69,844	73,664	110,106
Last Close Price	6020.00	6070.00	6234.53	7257.77	7822.22	10237.90
PE Ratio	9.09	9.17	5.12	6.43	7.97	19.21
PS Ratio	0.85	0.86	0.82	0.98	1.21	2.08
PB Ratio	0.45	0.45	0.50	0.65	0.79	1.13
P/TBV Ratio	0.46	0.46	0.51	0.66	0.80	1.15
P/FCF Ratio	8.11	8.18	5.93	56.56	29.03	16.41
P/OCF Ratio	5.91	5.96	3.22	5.79	7.08	11.50
EV/Sales Ratio	0.37	0.39	0.46	0.78	0.92	1.78
EV/EBITDA Ratio	2.21	2.33	1.98	3.61	4.07	8.80
EV/EBIT Ratio	4.00	4.22	2.71	4.99	5.39	13.80
EV/FCF Ratio	3.50	3.69	3.34	45.04	22.08	14.08
Debt / Equity Ratio	0.00	0.00	0.00	0.00	0.00	0.00
Debt / EBITDA Ratio	0.02	0.02	0.02	0.03	0.01	0.02
Debt / FCF Ratio	0.03	0.03	0.04	0.35	0.04	0.04
Net Debt / Equity Ratio	-0.26	-0.26	-0.23	-0.17	-0.19	-0.18
Net Debt / EBITDA Ratio	-2.91	-2.91	-1.60	-1.18	-1.28	-1.64
Net Debt / FCF Ratio	-4.61	-4.61	-2.70	-14.75	-6.96	-2.63
Asset Turnover	0.48	0.48	0.56	0.60	0.59	0.49
Inventory Turnover	2.06	2.06	2.15	2.42	2.40	2.22
Quick Ratio	4.06	4.06	3.32	3.27	2.95	3.46
Current Ratio	5.63	5.63	4.71	4.86	4.22	4.86
Return on Equity (ROE)	5.04%	5.04%	10.16%	10.57%	10.28%	6.05%
Return on Assets (ROA)	2.75%	2.75%	5.98%	5.92%	6.28%	3.93%
Return on Invested Capital (ROIC)	5.69%	5.71%	11.69%	12.04%	11.77%	6.88%
Return on Capital Employed (ROCE)	4.80%	4.80%	10.20%	10.10%	10.80%	6.80%
Earnings Yield	11.00%	10.91%	19.55%	15.55%	12.55%	5.21%
FCF Yield	12.33%	12.23%	16.85%	1.77%	3.45%	6.09%
Payout Ratio	29.16%	29.16%	13.74%	8.15%	8.89%	15.73%
Buyback Yield / Dilution	-	-	0.02%	-3.94%	1.05%	0.11%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.